BiotechTV - News - TopPodcast.com

Latest Episodes:

BIO-Europe 2025: AAVantgarde Bio, which is working on gene therapies for inherited retinal diseases that are caused by mutations in large genes, closed a $141M series B raise today Nov 03, 2025

Show notes

CEO Natalia Misciattelli describes the lead programs for Stargardt Disease and Usher 1B Syndrome, and how AAVantgarde is able to solve the problem of delivering genes that are naturally too large for single AAV vectors.

Mathai Mammen recaps the first clinical data Parabilis Medicines reported on its beta-catenin program earlier this month at EMSO and AACR-NCI-EORTC 2025. Plus, degraders for prostate cancer, and more. Oct 31, 2025

Show notes

He explains the company's "Helicon" peptide platform, and why he believes it is well suited to target previously undruggable problems like beta-catenin. Then he discusses clinical presentations on this program in multiple tumor types, and preclinical data on two degrader programs for prostate cancer.

BiotechTV visited South San Francisco based Noetik and saw how they are digitizing tumor samples and using AI to sort through the complexity of the biology for drug discovery Oct 30, 2025

Show notes

Co-Founder and CEO Ron Alfa walked BiotechTV's Ryan Flinn through how machine learning is taking cancer cell biology beyond the microscope.

Sonoma Biotherapeutics announced early clinical data today in a late-breaker at #ACR25 for its CAR-Treg to treat rheumatoid arthritis. Co-Founders Jeff Bluestone and Fred Ramsdell walk us through it. Oct 30, 2025

Show notes

They explain why they believe a Treg based cell therapy is the right approach for autoimmune conditions, and describe the construct of this particular product. After discussing the data, they also comment on what they believe the big picture is for these types of Treg based treatments going forward.

Zag Bio launched today with $80M, and aims to tackle autoimmune disease by using antibodies to reprogram how Tregs and Teffs are created in the thymus. The lead indication will be Type 1 diabetes Oct 28, 2025

Show notes

CEO Jason Cole walks us through this unique science, which is based on work that co-founder Diane Mathis and colleagues published in Cell in 2022. The T1D program is scheduled to be in the clinic by late 2026.

Hemab Therapeutics, a company specializing in developing treatments for bleeding disorders, announced a $157 million series C raise today. CEO Benny Sorensen describes the work and unmet need. Oct 27, 2025

Show notes

The company's lead program, a bi-specific called Sutacimig, has already reported phase 2 data for Glanzmann Thrombasthenia, and will start a pivotal in 2026. Hemab also has a monovalent antibody (HMB-022) in the clinic for the world's most common bleeding disorder, Von Willebrand Disease, and will be announcing an additional candidate next year.

Weave Bio, which raised a $20M series A this month, is aiming to use software and LLMs to automate and streamline regulatory submissions for drug development Oct 23, 2025

Show notes

Co-Founder & CEO Brandon Rice says that in one project it worked on with a pharma, Weave's technology took only 3 hours to draft regulatory documents what would have taken humans to 100 hours.

Ahead of a year of increased clinical activity, Entrada Therapeutics' CEO Dipal Doshi discusses the company's EEV platform, DMD programs, and a Vertex partnership in DM1 Oct 22, 2025

Show notes

He walks us through exon 44 and 45 programs, which will both likely have clinical readouts in 2026. Meanwhile, a $350M cash position gives Entrada the ability to think beyond neuromuscular conditions in the future as well.

Disc Medicine CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV) Oct 22, 2025

Show notes

He describes how Disc applied for and was awarded a CNPV for Bitopertin, which treats a rare disease that causes extreme sensitivity to sunlight. Plus, quickly ramping up a commercial team, and discussing Disc's two other development programs.

Biotech entrepreneurs share advice on navigating through today's uncertain times: "It's going to be okay" Oct 22, 2025

Show notes

MassBio CEO Kendalle Burlin O'Connell moderates a discussion with Normunity CEO Rachel Humphrey and Gallop Oncology CEO Luba Greenwood about how they are rising to today's challenges. Topics include the funding environment, motivating your team, storytelling, FDA Engagement, and perseverance.

Our TOPPODCAST Picks

Follow Us

Stay Connected

BiotechTV – News

Related Podcasts

Links

Stay Connected